Felix Cleemann

13 Patents

• US125444282026

  Controlled-release CNP Agonists with Reduced Side-effects

  ASCENDIS PHARMA GROWTH DISORDERS A/S

  0 cites
• US124537782025

  Incremental Dose Finding in Controlled-release PTH Compounds

  ASCENDIS PHARMA BONE DISEASES A/S

  0 cites
• US124031822025

  Liquid Pharmaceutical Formulations of PTH Conjugates

  ASCENDIS PHARMA BONE DISEASES A/S

  0 cites
• US122396892025

  Controlled-release CNP Agonists with Low Initial NPR-B Activity

  ASCENDIS PHARMA GROWTH DISORDERS A/S

  0 cites
• US122140202025

  PTH Prodrugs

  ASCENDIS PHARMA BONE DISEASES A/S

  0 cites
• US121569172024

  CNP Prodrugs with Carrier Attachment at the Ring Moiety

  ASCENDIS PHARMA GROWTH DISORDERS A/S

  0 cites
• US120831822024

  Controlled-release CNP Agonists with Increased NEP Stability

  ASCENDIS PHARMA GROWTH DISORDERS A/S

  0 cites
• US119186282024

  Controlled-release PTH Compound

  ASCENDIS PHARMA BONE DISEASES A/S

  0 cites
• US118903262024

  Controlled-release PTH Compound

  ASCENDIS PHARMA BONE DISEASES A/S

  0 cites
• US118576032024

  PTH Compounds with Low Peak-to-trough Ratios

  ASCENDIS PHARMA BONE DISEASES A/S

  0 cites
• US117938612023

  PTH Prodrugs

  ASCENDIS PHARMA BONE DISEASES A/S

  0 cites
• US117595042023

  PTH Compounds with Low Peak-to-trough Ratios

  Ascendis Pharma Bone Diseases A/S

  0 cites
• US116334872023

  Prodrugs Comprising an Aminoalkyl Glycine Linker

  ASCENDIS PHARMA A/S

  0 cites